<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168493">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00903877</url>
  </required_header>
  <id_info>
    <org_study_id>SU-04272009-2419</org_study_id>
    <secondary_id>16295</secondary_id>
    <nct_id>NCT00903877</nct_id>
  </id_info>
  <brief_title>Study of T3 for the Treatment of Fibromyalgia</brief_title>
  <official_title>T3 for Fibromyalgia: a Pilot Double-blind Non-randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      Determine if T3 - the active form of thyroid hormone - is beneficial in fibromyalgia.
      Determine the feasibility and promise of an appropriately powered future prospective
      randomized controlled study of using T3 (the active form of thyroid hormone) for the
      treatment of fibromyalgia. We specifically aim to assess the feasibility, cost, obstacles
      and promise of conducting a prospective controlled study in the future.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analogue scale of pain intensity</measure>
    <time_frame>Duration of the trial</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>T3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T3</intervention_name>
    <description>Patients receive T3 in a dose of 25mcg and 50mcg</description>
    <arm_group_label>T3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients receive a sugar pill</description>
    <arm_group_label>Placebo - sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-50

          2. Meet american college of rheumatology criteria for fibromyalgia

          3. at baseline report an average pain of 4 or more on a brief Pain Inventory.

          4. can climb 2 flights of stairs without shortness of breath.

        Exclusion Criteria:

          1. new medication change in the last 2 months

          2. any cardiac disease at all

          3. known thyroid disease before or after thyroid screening bloodwork

          4. unstable medical or psychiatric disease.

          5. Known inflammatory or rheumatic disease other than fibromyalgia

          6. substance abuse in the last year

          7. suicidality or depression as indicated by a Beck Depression Inventory of 30 or above

          8. concomitant herbal medications

          9. multiple severe medication allergies

         10. the assessment of the research team that inclusion of the subject could in some way
             compromise the safety and validity of the study.

         11. diabetes

         12. smoking

         13. Known uncontrolled hypertension

         14. known uncontrolled hypercholesterolemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian R Carroll</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <lastchanged_date>June 21, 2012</lastchanged_date>
  <firstreceived_date>May 15, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Sean Mackey</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
